Cargando…

Programmed Death-1(PD-1), a correlate of protection against disease progression in HIV-1 infected long-term non-progressors

Detalles Bibliográficos
Autor principal:	Kyosiimire-Lugemwa, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441795/ http://dx.doi.org/10.1186/1742-4690-9-S2-P254

Ejemplares similares

P16-16. Gag and Nef specific T-cell responses in HIV-1 infected long-term non-progressors in Uganda
por: Kyosiimire-Lugemwa, J, et al.
Publicado: (2009)

Anti-CD4-gp120 complex antibodies in long-term non-progressors HIV-1 positive patients: a role in slowing disease progression?
por: Burastero, Samuele, et al.
Publicado: (2006)

Preferential targeting of co-evolving Gag residues in long-term non progressors
por: Sunshine, J, et al.
Publicado: (2012)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
por: Bertsias, G, et al.
Publicado: (2005)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

HIV-specific T-cell Responses and Generalized Activation in HIV-1 Infected Long-term Non-progressors and Progressors from South India
por: Swathirajan, Chinnambedu Ravichandran, et al.
Publicado: (2018)

Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients
por: Ramírez de Arellano, Eva, et al.
Publicado: (2019)

What do we learn from a Genome Wide Association Study performed on HIV-1 infected Long Term Non Progressors individuals?
por: Guergnon, Julien, et al.
Publicado: (2009)

Long term non-progressor (LTNP) HIV infection
por: Kumar, Praveen
Publicado: (2013)

Comparable antiviral capacity but favorable in vitro survival of CD8s from elite controllers compared to untreated progressors
por: Shasha, D, et al.
Publicado: (2012)

Bridging HIV-1 Cellular Latency and Clinical Long-Term Non-Progressor: An Interactomic View
por: Yang, Jin, et al.
Publicado: (2013)

Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera
por: Hao, Yuxia, et al.
Publicado: (2015)

Meta-analysis of gene expression profiles in long-term non-progressors infected with HIV-1
por: Lee, Sun Young, et al.
Publicado: (2019)

Are Long-Term Non-Progressors Very Slow Progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988–2010
por: Mandalia, Sundhiya, et al.
Publicado: (2012)

A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression
por: Snoek, Joke, et al.
Publicado: (2011)

P16-28. The first year: early correlates of long-term HIV progression
por: Chattopadhyay, PK, et al.
Publicado: (2009)

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie, et al.
Publicado: (2014)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

Monocyte Based Correlates of Immune Activation and Viremia in HIV-Infected Long-Term Non-Progressors
por: Prabhu, Varsha M., et al.
Publicado: (2019)

HIV specific Th1 responses are altered in Ugandans with HIV and Schistosoma mansoni coinfection
por: Obuku, Andrew Ekii, et al.
Publicado: (2023)

Factors associated with conversion of long-term non-progressors to progressors: A prospective study of HIV perinatally infected paediatric survivors
por: Radhakrishna, Muttineni, et al.
Publicado: (2013)

P16-05. Upregulation of PD-1 and CTLA-4 on HIV-specific T cells in HIV-infected infants
por: Nqoko, BS, et al.
Publicado: (2009)

The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients
por: Van Duyne, Rachel, et al.
Publicado: (2010)

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
por: González, Nuria, et al.
Publicado: (2018)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions
por: Lussier, Danielle M, et al.
Publicado: (2013)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway
por: Luz-Crawford, Patricia, et al.
Publicado: (2012)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data
por: Ghebeh, Hazem, et al.
Publicado: (2015)

HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals
por: van den Kerkhof, TL, et al.
Publicado: (2012)

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors
por: Hayashida, Tsunefusa, et al.
Publicado: (2017)

KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors
por: Jiang, Yongjun, et al.
Publicado: (2013)

Protective effect of KIR3DS1 in asymptomatic HIV-1 seroconverters towards AIDS
por: Stalinraja, M, et al.
Publicado: (2012)

Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses
por: Srivastava, Minu, et al.
Publicado: (2015)

Identification of human monoclonal antibodies specific for CCR5 from an antibody library derived from HIV-infected long-term non-progressors
por: Zhang, Mei-Yun, et al.
Publicado: (2006)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_48g24t80u1ur1hdsjetilfif3k